Overview

Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This study will further analyze the use of ceftaroline for CABP and compare its potential to eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of ceftaroline compared to levofloxacin may be further highlighted from this investigation.
Phase:
Phase 4
Details
Lead Sponsor:
Gary E. Stein, Pharm.D.
Collaborator:
Forest Laboratories
Treatments:
Ceftaroline fosamil
Levofloxacin
Ofloxacin